Do Race, Insurance Status, and Income Factors Impact Pathologic Fracture Presentation and Management?
Open Access
- 22 September 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (18) , e71201
Abstract
Introduction: Metastatic bone disease (MBD) and pathologic fractures (PF) can impact quality of life, functionality, and survival. Understanding the management of PF and access to care and treatment in the U.S. healthcare system can improve patient outcomes, directly impacting treatment eligibility and overall survival. We ask: (1) Do race, income, and insurance status differ between prophylactic stabilization of impending and acute fixation of overt PF, respectively? (2) Are race, income, and insurance status associated with complications in patients with metastatic bone disease? (3) Are race, income, and insurance associated with length of stay and insurance type in patients with MBD? Methods: The NIS HCUP database was queried from 2016 to 2020 for pathological fractures. We then identified patients with associated cancer ICD‐10 diagnostic codes for the hospitalization (breast, prostate, renal, lung, thyroid, bone, and other). General linear models (GLMs) were used to answer each clinical question. We conducted a post hoc analysis of the other malignancies associated with osseous metastasis and performed the same studies as above. Results: We found 2050 prophylactically stabilized impending and 4181 acute fractures. There were no differences among races, income, or insurance status and the prevalence of impending versus acute fractures. We found that Black patients were more likely to have complications, while Hispanic patients were the least likely, compared to other races. Black patients had higher hospital costs, while both Black and Hispanic patients had more extended hospitalizations and were more likely to have Medicaid or no insurance compared to other races. Our post hoc analyses found that the rate of impending and acute fractures differed among race, income, and insurance status, depending on the metastatic cause. Conclusions: We identified healthcare disparities in patients with impending and overt PF due to MBD despite minimal to no differences in patient comorbidities, fracture management, or hospitalization complications.Keywords
This publication has 30 references indexed in Scilit:
- Adherence to Methodological Standards in Research Using the National Inpatient SampleJAMA, 2017
- Racial and Socioeconomic Disparities in Hip Fracture CareJournal of Bone and Joint Surgery, 2016
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) StatementPLOS Medicine, 2015
- Editorial: Large Database Studies—What They Can Do, What They Cannot Do, and Which Ones We Will PublishClinical Orthopaedics and Related Research, 2015
- Limitations of Administrative DatabasesJAMA, 2012
- Surveillance Bias in Outcomes ReportingJAMA, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJournal of Clinical Epidemiology, 2008
- Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysisThe Lancet Oncology, 2008
- Economic burden of metastatic bone disease in the U.S.Cancer, 2007
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006